Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at Progression

NCT06333314 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT06333314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06333314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at Progression
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Recruiting
Start date
July 23, 2024
Completion date
September 30, 2030
Enrollment
120 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

adrenocortical carcinoma, ampulla of vater carcinoma, duodenum adenocarcinoma, gastric adenocarcinoma, neuroendocrine carcinoma, pancreatic adenocarcinoma, small bowel adenocarcinoma, soft tissue sarcoma